19
Aug
2016

Illumina Takeout? Ha!, Portola Stumbles, and NYT Biotech Ace Moves On

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

RevMed’s Rollout, Yosemite Invests in Cancer & Servier’s Phase III Whiff
Anthropic Makes Noise, Silence Gets Bought, & GSK Gets HepB OK
BMS Hits IPF Goal, Iambic and City IPO & AZ Invests in Insitro
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO